Cognitive adverse events in patients with lung cancer treated with checkpoint inhibitor monotherapy: a propensity score-matched analysisResearch in context

Cognitive adverse events in patients with lung cancer treated with checkpoint inhibitor monotherapy: a propensity score-matched analysisResearch in context

Summary: Background: Cancer-related cognitive decline is a serious problem in long-term survival but no pivotal study has investigated whether checkpoint inhibitors (ICI) may be associated with cognitive adverse events. Methods: This propensity score-matched analysis recruited non-small cell lung c...

Full description

Bibliographic Details
Main Authors:	Yifei Ma, Nianqi Liu, Yanqi Wang, Ao Zhang, Zirui Zhu, Zhiying Zhang, Yiming Li, Guangmin Jian, Guangzhen Fu, Mingming Dong, Guoxing Zheng, Pengfei Zhu, Guanqing Zhong, Shenrui Bai, Shuqin Chen, Xiaolong Wei, Jifan Tan, Xinjia Wang
Format:	Article
Language:	English
Published:	Elsevier 2023-05-01
Series:	EClinicalMedicine
Subjects:	Checkpoint inhibitor Cognitive adverse events Minimal clinically important difference Propensity score matching Immune-related adverse events
Online Access:	http://www.sciencedirect.com/science/article/pii/S2589537023001645

Similar Items

Immune checkpoint inhibitors and cancer-related cognitive decline: a propensity score matched analysis in active chemotherapy patients
by: Guangmin Jian, et al.
Published: (2025-03-01)

Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysisResearch in context
by: Anand V. Kulkarni, et al.
Published: (2023-09-01)

A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system
by: Zhihong Fang, et al.
Published: (2023-06-01)

The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis
by: Hou H, et al.
Published: (2019-05-01)

Pharmacovigilance in Vaccines: Importance, Main Aspects, Perspectives, and Challenges—A Narrative Review
by: Katharine Valéria Saraiva Hodel, et al.
Published: (2024-06-01)

Adverse events: an expensive and avoidable hospital problem
by: Diego San Jose-Saras, et al.
Published: (2022-12-01)

IL12/23 Blockade with Ustekinumab as a Treatment for Immune-Related Cutaneous Adverse Events
by: Stephanie L. Gu, et al.
Published: (2023-11-01)

Topiramate Monotherapy in Epilepsy
by: J Gordon Millichap
Published: (2009-09-01)

Propensity-Score-Matched Evaluation of Adverse Events Affecting Recovery after COVID-19 Vaccination: On Adenovirus and mRNA Vaccines
by: Chang-Sik Son, et al.
Published: (2022-02-01)

Favorable Effects of Tacrolimus Monotherapy on Myasthenia Gravis Patients
by: Zhirong Fan, et al.
Published: (2020-10-01)

Evaluate the renal system damage caused by zoledronic acid: a comprehensive analysis of adverse events from FAERS
by: Zhaojun Wang, et al.
Published: (2024-12-01)

Effects of secukinumab and ixekizumab on major adverse cardiovascular events in patients with psoriasis: a meta-analysis of randomized controlled trials
by: Yonghong Zhang, et al.
Published: (2024-03-01)

Reducing preventable adverse events in obstetrics by improving interprofessional communication skills – Results of an intervention study
by: Beate Hüner, et al.
Published: (2023-01-01)

Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system
by: Xianglin Pan, et al.
Published: (2024-07-01)

Magnitude and Impacts of Adverse Events of Injectable Containing Shorter Regimen in Programmatic Management of Multi-Drug Resistant Tuberculosis in Ethiopia: A Retrospective Cohort Study
by: Achalu DL, et al.
Published: (2023-11-01)

Blood transfusion adverse event management system: construction and application
by: Xuemin WU, et al.
Published: (2023-11-01)

Safety assessment of sulfasalazine: a pharmacovigilance study based on FAERS database
by: Wangyu Ye, et al.
Published: (2024-09-01)

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib
by: Xusheng Zhang, et al.
Published: (2024-07-01)

Cosmetics utilization and associated adverse events: A community based cross-sectional study
by: Sweta Kumari, et al.
Published: (2023-09-01)

Pharmaceutical systematics: Description and preliminary investigation of an alternative method for structuring drug information
by: Mary E. Kiersma, et al.
Published: (2011-01-01)

Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma
by: Yoko Maegawa, et al.
Published: (2020-09-01)

Post-marketing drug safety surveillance of enfortumab vedotin: an observational pharmacovigilance study based on a real-world database
by: Mingming Yu, et al.
Published: (2024-08-01)

OAE-based data mining and modeling analysis of adverse events associated with three licensed HPV vaccines
by: Wenrui Zi, et al.
Published: (2022-11-01)

Comparative analysis of adverse event risks in breast cancer patients receiving pembrolizumab combined with paclitaxel versus paclitaxel monotherapy: insights from the FAERS database
by: Yilun Li, et al.
Published: (2024-08-01)

Adverse event reporting following immunization of hepatitis B vaccine: A 13-year review
by: Xiaoying Gong, et al.
Published: (2024-12-01)

Reducedhumoral response against variants of concern in childhood solid cancer patients compared to adult patients and healthy children after SARS-CoV-2 vaccination
by: Yifei Ma, et al.
Published: (2023-05-01)

Adverse drug reactions in psychiatry outpatient department of a tertiary care hospital in Western Uttar Pradesh: An observational study
by: Jaspreet Kaur Sidhu, et al.
Published: (2022-01-01)

Awareness, attitude, and practice of materiovigilance among medical professionals at a tertiary care institute of national importance: A cross-sectional study
by: Bikash Ranjan Meher, et al.
Published: (2022-01-01)

PSA LEVEL AND ADVERSE EVENTS IN SIXTH AND TENTH SERIES DOCETAXEL CHEMOTHERAPY IN CASTRATE-RESISTANT PROSTATE CANCER (CRPC) PATIENTS
by: Kurnia Penta Seputra, et al.
Published: (2025-01-01)

Nebivolol induced hyperkalemia: case report
by: Karmela Altabas, et al.
Published: (2016-01-01)

Three aspects of acupuncture-related adverse events: Issues around the reporting of acupuncture-related adverse events
by: Tae-Hun Kim, et al.
Published: (2023-09-01)

Subacute neuronopathy in a young man: a possible association with tetracycline treatment
by: Björn Lindvall, et al.
Published: (2011-11-01)

Peripheral polyneuropathy in patients receiving long-term statin therapy
by: Öner Özdogan
Published: (2019-10-01)

Perception of the Disclosure of Adverse Events in a Latin American Culture: A National Survey
by: Thiago Gomes Romano, et al.
Published: (2022-08-01)

Hallucination: A rare complication of levetiracetam theraphy
by: Seher Erdogan, et al.
Published: (2017-11-01)

Global Assessment of Pediatric Patient Safety Tool for identifying safety incidents in pediatric patients
by: Marilise Borges Brandão, et al.
Published: (2023-05-01)

The Rise of Patient Safety-II: Should We Give Up Hope on Safety-I and Extracting Value From Patient Safety Incidents?; Comment on “False Dawns and New Horizons in Patient Safety Research and Practice”
by: Andrew Carson-Stevens, et al.
Published: (2018-07-01)

Critical Overview on the Benefits and Harms of Aspirin
by: Chun Shing Kwok, et al.
Published: (2010-05-01)

Cardiovascular toxicity of tisagenlecleucel in children and adolescents: analysis of spontaneous reports submitted to FAERS
by: Ganggang Wang, et al.
Published: (2025-01-01)

Dexmedetomidine: a real-world safety analysis based on FDA adverse event reporting system database
by: Yichun Shuai, et al.
Published: (2024-08-01)